Molecular and cellular mechanisms of the FVIII immune response
Molecular and cellular mechanisms of the FVIII immune response
批准号:
10162322
负责人:
Valder R. Arruda
金额:
$139.61万
依托单位国家:
美国
项目类别:
财政年份:
2018
资助国家:
美国
项目状态:
已结题
起止时间:
2018-05-01 至 2023-04-30
关键词:
AddressAnimalsAntibodiesAntibody FormationAntigen-Presenting CellsAreaAutomobile DrivingB cell repertoireB-Cell ActivationB-LymphocytesBackBasic ScienceBiochemicalBiologicalBiologyCD4 Positive T LymphocytesCanis familiarisCaringCell SurvivalCellsClinicalComplicationDevelopmentElementsEnvironmental Risk FactorEventF8 geneFactor VIIIGenomicsGoalsGrowthHemophilia AImmune responseImmune signalingInternational AspectsInvestigationLife Cycle StagesLinkLongitudinal StudiesMolecularMorbidity - disease ratePF4 GenePathogenicityPatientsPlayPropertyRecordsResearchResearch PersonnelRoleSeveritiesSignal TransductionStructureT-Cell ActivationTechniquesTestingTherapeutic InterventionVWF geneVisualizationcytokinedesignenzyme replacement therapygut microbiomehost microbiomeimmunogenicityin vivoinhibitor/antagonistinnate immune sensinginnovationinnovative technologiesinsightinterestmicrobiomemortalitynovelnovel therapeutic interventionpreventprogramsresponse
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Overall Program-Abstract
The formation of inhibitory antibodies to infused factor VIII (FVIII) remains one of the most challenging
complications of protein replacement therapy in hemophilia A (HA) patients and it is associated with increase
morbidity and mortality. This U54 application assembles a cross-disciplinary team of investigators with
appropriate track records, research interests and synergistic expertise to address unanswered mechanistic
questions related to FVIII immunogenicity. Our innovative scientific program is well-integrated, tests new
hypotheses and brings novel innovative technologies and investigators from a wide range of background to
better understand FVIII immunogenicity Project 1 (Arruda/Milone): Characterization of the functional
repertoire and ontogeny of FVIII humoral response across species. Studies using immunoproteomics and
genomics to help rigorously determine the ontogeny of the inhibitor producing cells in HA patients. They will
define the B cell repertoires responsible for the inhibitors in these patients and in longitudinal studies in HA
dogs with inhibitors. Moreover, the will define the emerging role of B cell survival cytokine in the context of
FVIII inhibitors. Project 2 (Herzog): In vivo Mechanism of Immune Response to Factor VIII. Utilizing
innovative strategies, including in vivo visualization techniques to define which antigen presenting cells (APCs)
are required for MHC II presentation to CD4+ T cells how these APCs interact to prime FVIII-specific CD4+ T
cells, which subsets of CD4+ T cells are induced to promote B cell activation, and how innate immune signaling
and the microbiome may alter these events. Project 3 (Lillicrap): Influence of the host microbiome on the
mechanism of FVIII immunogenicity. Innovative preliminary observations linking elements of the gut
microbiome in determining the FVIII-specific immune response. Employing animal studies to investigate the
modulatory role of the host gut microbiome on the immune response to FVIII. This novel line of investigation is
proposed to reveal a critical link between environmental factors and variability in the development of inhibitory
antibodies to FVIII. Project 4 (Camire/Krishnaswamy): Factor VIII Immunogenicity-Biology and Structure.
This project centers on the role of various molecular species relevant to the biological life cycle of FVIII in
regulating the immune response and inhibitor development. Using biochemical and structural biological
approaches to focus on the properties of FVIII driving the immune response. A major hypothesis to be pursued
under this project relates to the role played by the interaction between FVIII and vWF as a modulator of
inhibitor formation. The multi-pronged approach contained in this integrated proposal derives from the
established areas of expertise of the participating investigators and provides a comprehensive investigation
into the multiple biological mechanisms underlying the immunogenicity of FVIII.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Immune tolerance induction by AAV-FVIII gene therapy for canine hemophilia A with inhibitors
-
批准号:10276571
-
项目类别:
-
资助金额:$74.62万
-
财政年份:2021
-
负责人:Valder R. Arruda
-
依托单位:
Characterization of the Functional Repertoire and Ontogeny of FVIII Humoral Response Across Species: Project 1
-
批准号:10406333
-
项目类别:
-
资助金额:$34.62万
-
财政年份:2018
-
负责人:Valder R. Arruda
-
依托单位:
Biochemistry of Intrinsic Xase
-
批准号:10439608
-
项目类别:
-
资助金额:$73.28万
-
财政年份:2018
-
负责人:Valder R. Arruda
-
依托单位:
Skills Development
-
批准号:10406332
-
项目类别:
-
资助金额:$27.68万
-
财政年份:2018
-
负责人:Valder R. Arruda
-
依托单位:
Characterization of the Functional Repertoire and Ontogeny of FVIII Humoral Response Across Species: Project 1
-
批准号:10162324
-
项目类别:
-
资助金额:$34.93万
-
财政年份:2018
-
负责人:Valder R. Arruda
-
依托单位:
Skills Development
-
批准号:10162323
-
项目类别:
-
资助金额:$27.68万
-
财政年份:2018
-
负责人:Valder R. Arruda
-
依托单位:
Biochemistry of Intrinsic Xase
-
批准号:10175003
-
项目类别:
-
资助金额:$73.28万
-
财政年份:2018
-
负责人:Valder R. Arruda
-
依托单位:
Novel Therapy for Hemophilia B Using AAV-FIX Variants
-
批准号:8185311
-
项目类别:
-
资助金额:$38.44万
-
财政年份:2011
-
负责人:Valder R. Arruda
-
依托单位:
AAV2-F.IX Hepatic Gene Transfer under Immunomodulation
-
批准号:7078208
-
项目类别:
-
资助金额:$38.04万
-
财政年份:2006
-
负责人:Valder R. Arruda
-
依托单位:
AAV2-F.IX Hepatic Gene Transfer under Immunomodulation
-
批准号:7246535
-
项目类别:
-
资助金额:$36.24万
-
财政年份:2006
-
负责人:Valder R. Arruda
-
依托单位:
AAV2-F.IX Hepatic Gene Transfer under Immunomodulation
-
批准号:7435223
-
项目类别:
-
资助金额:$37.12万
-
财政年份:2006
-
负责人:Valder R. Arruda
-
依托单位:
Intravascular Delivery of AAV to Skeletal Muscle
-
批准号:6959243
-
项目类别:
-
资助金额:$45.83万
-
财政年份:2005
-
负责人:Valder R. Arruda
-
依托单位:
Efficacy and Safety of AAV Gene Transfer for Hemophilia
-
批准号:6784581
-
项目类别:
-
资助金额:$9.68万
-
财政年份:2002
-
负责人:Valder R. Arruda
-
依托单位:
Efficacy and Safety of AAV Gene Transfer for Hemophilia
-
批准号:6653975
-
项目类别:
-
资助金额:$9.68万
-
财政年份:2002
-
负责人:Valder R. Arruda
-
依托单位:
Efficacy and Safety of AAV Gene Transfer for Hemophilia
-
批准号:6418969
-
项目类别:
-
资助金额:$9.68万
-
财政年份:2002
-
负责人:Valder R. Arruda
-
依托单位:
Intravascular Delivery of AAV to Skeletal Muscle
-
批准号:7417865
-
项目类别:
-
资助金额:$52.53万
-
财政年份:--
-
负责人:Valder R. Arruda
-
依托单位:
Biochemistry of Intrinsic Xase
-
批准号:9982421
-
项目类别:
-
资助金额:$49.52万
-
财政年份:--
-
负责人:Valder R. Arruda
-
依托单位:
Intravascular Delivery of AAV to Skeletal Muscle
-
批准号:7312513
-
项目类别:
-
资助金额:$50.46万
-
财政年份:--
-
负责人:Valder R. Arruda
-
依托单位:
Novel Therapy for Hemophilia B Using AAV-FIX Variants
-
批准号:8502298
-
项目类别:
-
资助金额:$49.36万
-
财政年份:--
-
负责人:Valder R. Arruda
-
依托单位:
Novel Therapy for Hemophilia B Using AAV-FIX Variants
-
批准号:8691967
-
项目类别:
-
资助金额:$50.72万
-
财政年份:--
-
负责人:Valder R. Arruda
-
依托单位:
海外基金